

12-16-99

Box 500
Express Mail No. EL440267232US
Attorney Docket No. 6056-260

PATENT APPLICATION TRANSMITTAL LETTER

In re: Application of:

Keith R. McCrae

jc713 U.S. PTO



Filed: Concurrently Herewith

12/15/99

For: INHIBITION OF ANGIOGENESIS BY HIGH
MOLECULAR WEIGHT KININOGEN DOMAIN
3 PEPTIDE ANALOGS

ASSISTANT COMMISSIONER FOR PATENTS
BOX PATENT APPLICATIONS
WASHINGTON, D.C. 20231

jc530 U.S. PTO
09/461061
12/15/99

Dear Sir:

Enclosed are the following documents:

- ☒ 34 pages of specification and 1 page of Abstract.
- ☐ sheets of formal drawings.
- ☒ Declaration and Power of Attorney (signed and attached to application).
- ☒ Statement Pursuant to 37 C.F.R. 1.821(f).
- ☒ Sequence Listing Diskette.
- ☒ Sequence Listing (8 pages).
- ☐ Power of Attorney by Assignee of Entire Interest (Revocation of Prior Powers).
- ☒ Information Disclosure Statement with Substitute PTO-1449 (in dupl) and 12 references.
- ☐ Transmittal of Priority Document and Priority Document.

The filing fee has been calculated as shown below:

CLAIMS AS FILED	HIGHEST NO. PAID FOR	PRESENT EXTRA
TOTAL	54 - 20 =	34
INDEP.	8 - 3 =	5
[X] Multiple Dependent Claim Presented		

SMALL ENTITY RATE	FEE
x 9 =	0
x 39 =	0
+ 130	
TOTAL	\$ 0

OTHER THAN SMALL ENTITY	FEE
x 18 =	612
x 78 =	390
+ 260 =	260
TOTAL	\$2022.00


CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10

EXPRESS MAIL Mailing Label Number: EL440267232US Date of Deposit: 15 December 1999
I hereby certify that this paper and/or fee is being deposited with the United States Postal Service, "EXPRESS MAIL - POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and is addressed to the Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Tammy L. Cipparone
(Name of person mailing paper)

(Signature of person mailing paper)

- [X] Please charge my Deposit Account No. 19-1135 in the amount of \$2022.00. A duplicate copy of this sheet is enclosed.
- [] A check in the amount of \$_____ is enclosed.
- [X] The Commissioner is hereby authorized to charge payment of the following fee associated with this communication or credit any overpayment to Deposit Account No. 19-1135. A duplicate copy of this sheet is enclosed.
- [X] Any filing fees under 37 CFR 1.16 for the presentation of extra claims.
- [X] Any patent application processing fees under 37 CFR 1.17.
- [] The Commissioner is hereby authorized to charge payment of the following fees during pendency of this application or credit any overpayment to Deposit Acct. No. 19-1135. A duplicate copy of this sheet is enclosed.
- [] Any filing fees under 37 CFR 1.16 for the presentation of extra claims.
- [] Any patent application processing fees under 37 CFR 1.17.
- [] The Issue Fee set in 37 CFR §1.18 or before mailing of the Notice of Allowance, pursuant to 37 CFR §1.31(b).


GREGORY J. LAVORGNA
Registration No. 30,469
SEIDEL, GONDA, LAVORGNA
& MONACO, P.C.
1800 Two Penn Center
Philadelphia, PA 19102
Telephone No.: (215) 568-8383
Facsimile No.: (215) 568-5549

Attorney for Applicant

- 1 -

"EXPRESS MAIL" mailing label number
EL44026713245 Date of Deposit 12/15/99

I hereby certify that this paper or fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" as required under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231

John V. Parone
Name of Person Mailing Paper or Fee
Type of Print Name

Signature of Person Mailing Paper or Fee

**INHIBITION OF ANGIOGENESIS BY HIGH MOLECULAR
WEIGHT KININOGEN DOMAIN 3 PEPTIDE ANALOGS**

Cross-Reference to Related Application

The benefit of U.S. provisional patent application 60/112,427 filed
5 December 16, 1998 is hereby claimed. The entire disclosure of application
60/112,427 is incorporated herein by reference.

Field of the Invention

The invention relates to therapeutic compounds and methods for
inhibiting angiogenesis.

10

Background of the Invention

Angiogenesis

15

20

Angiogenesis is the process in which new blood vessels grow into
an area which lacks a sufficient blood supply. Angiogenesis commences
with the erosion of the basement membrane surrounding endothelial cells
and pericytes forming capillary blood vessels. Erosion of the basement
membrane is triggered by enzymes released by endothelial cells and
leukocytes. The endothelial cells then migrate through the eroded
basement membrane when induced by angiogenic stimulants. The
migrating cells form a "sprout" off the parent blood vessel. The migrating
endothelial cells proliferate, and the sprouts merge to form capillary loops,
thus forming a new blood vessel.

- 2 -

Angiogenesis can occur under certain normal conditions in mammals such as in wound healing, in fetal and embryonic development, and in the formation of the corpus luteum, endometrium and placenta. Angiogenesis also occurs in certain disease states such as in tumor formation and expansion, or in the retina of patients with certain ocular disorders. Angiogenesis can also occur in a rheumatoid joint, hastening joint destruction by allowing an influx of leukocytes with subsequent release of inflammatory mediators.

The evidence for the role of angiogenesis in tumor growth was extensively reviewed by O'Reilly and Folkman in U.S. Pat. 5,639,725, the entire disclosure of which is incorporated herein by reference. It is now generally accepted that the growth of tumors is critically dependent upon this process. Primary or metastatic tumor foci are unable to achieve a size of more than approximately 2 mm in the absence of neovascularization. Serial evaluation of transgenic mice predisposed to develop neoplasms has demonstrated that neovascularization of premalignant lesions precedes their evolution into tumors (Folkman *et al.*, *Nature* 339:58-61, 1989), and that inhibition of angiogenesis delays the growth of such lesions, as well as their assumption of a malignant phenotype (Hanahan *et al.*, *Cell* 86:353-364, 1996). In humans, several studies have demonstrated that increased density of microvessels within a tumor is associated with a poor clinical outcome (Weidner *et al.*, *J Natl Cancer Inst* 84:1875-1887, 1992).

An emerging paradigm is that proteolytic fragments of plasma or extracellular matrix proteins regulate angiogenesis. To date, several polypeptides with such activities have been identified. These include angiostatin, which contains kringles 1-4 plasminogen (O'Reilly *et al.*, *Cell* 79:315-328, 1994), endostatin, a 20 kD C-terminal fragment of collagen XVIII (O'Reilly *et al.*, *Cell* 88:277-285, 1997), PEX, the hemopexin domain of matrix metalloprotease 2 (Brooks *et al.*, *Cell* 92:391-400, 1998), the C-terminal 16 kD fragment of prolactin (Clapp *et al.*, *Endocrinol* 133:1292-1299, 1993) and a 29 kD fragment of fibronectin (Homandberg *et al.*, *Am*

- 3 -

J Pathol 120:327-332, 1985). In addition, both intact thrombospondin 1 as well as peptides derived from its procollagen domain and properdin-like type-1 repeats express potent anti-angiogenic activity (Good *et al.*, *Proc Nat Acad Sci USA* 87:6624-6628, 1990); Tolsma *et al.*, *J Cell Biol* 122:497-511, 1993. In preclinical models, several of these fragments inhibited tumor growth, and some induced tumor regression and dormancy (Boehm *et al.*, *Nature* 390:404-407, 1997).

High Molecular Weight Kininogen

High molecular weight kininogen (HK) is a 120 kD glycoprotein containing heavy and light chains, comprised of domains 1 through 3, and 5 and 6, respectively (Kaplan *et al.*, *Blood* 70:1-15, 1987). The heavy and light chains are linked by domain 4, which contains bradykinin, a nonapeptide which mediates several events including NO-dependent vasodilation (Weimer *et al.*, *J Pharm Exp Therapeutics* 262:729-733, 1992). HK (also referred to as "single chain high molecular weight kininogen") binds with high affinity to endothelial cells, where it is cleaved to two-chain high molecular weight kininogen (HK_a) by plasma kallikrein. Bradykinin is released from HK through cleavage mediated by plasma kallikrein (Kaplan *et al.*, *Blood* 70:1-15, 1987). This event occurs on the surface of endothelial cells following the activation of prekallikrein to kallikrein by an endothelial cell protease (Motta *et al.*, *Blood* 91:515-528, 1998). Cleavage of HK to form HK_a and release bradykinin occurs between Lys(362) and Arg(363). HK_a contains a 62 kD heavy chain and a 56 kD light chain linked by a disulfide bond.

Conversion of HK to HK_a is accompanied by a dramatic structural rearrangement, which has been demonstrated using rotary shadowing electron microscopy (Weisel *et al.*, *J. Biol Chem* 269:10100-10106, 1994). HK_a, but not HK, has been shown to inhibit the adhesion of endothelial and other cell types to vitronectin (Asakura, *J. Cell Biol* 116:465-476, 1992). HK_a, but not HK, also binds tightly to artificial anionic surfaces.

- 4 -

HK domain 3 consists of HK amino acids Gly(235)-Met(357). HK domain 3 has the following amino acid sequence:

5 Gly-Lys-Asp-Phe-Val-Gln-Pro-Pro-Thr-Lys-Ile-Cys-Val-Gly-Cys-Pro-
Arg-Asp-Ile-Pro-Thr-Asn-Ser-Pro-Glu-Leu-Glu-Glu-Thr-Leu-Thr-His-
Thr-Ile-Thr-Lys-Leu-Asn-Ala-Glu-Asn-Asn-Ala-Thr-Phe-Tyr-Phe-
Lys-Ile-Asp-Asn-Val-Lys-Lys-Ala-Arg-Val-Gln-Val-Val-Ala-Gly-Lys-
Lys-Tyr-Phe-Ile-Asp-Phe-Val-Ala-Arg-Glu-Thr-Thr-Cys-Ser-Lys-Glu-
Ser-Asn-Glu-Glu-Leu-Thr-Glu-Ser-Cys-Glu-Thr-Lys-Lys-Leu-Gly-
10 Gln-Ser-Leu-Asp-Cys-Asn-Ala-Glu-Val-Tyr-Val-Val-Pro-Trp-Glu-Lys-
Lys-Ile-Tyr-Pro-Thr-Val-Asn-Cys-Gln-Pro-Leu-Gly-Met (SEQ ID
NO:18).

HK binds to endothelial cells, platelets and neutrophils in the intravascular compartment. A specific cell attachment site has been identified on HK domain 3 by an antibody-directed strategy utilizing an
15 antibody HKH15, selected for its ability to block HK binding to cells (Herwald *et al.*, *J. Biol Chem* 270:14634-14642 (1995). A series of HK domain 3 synthetic peptides was examined for ability to inhibit biotin-HK from binding to human umbilical vein endothelial cells. As a result, the cell binding site was localized to a domain 3 segment containing HK amino
20 acids Leu(331)-Met(357). Other weakly inhibiting peptides include Lys(224)-Pro(254), Asn(276)-Ile(301) and Leu(331)-Met(357). However, the effect on endothelial cell proliferation was not studied.

Summary of the Invention

The compounds of the present invention are in the form of peptides
25 which possess anti-angiogenic activity.

In all embodiments, the peptide may optionally comprise an amino-terminal and/or carboxy-terminal protecting group.

Compounds of the formula X_1 -SEQ ID NO:1- X_2 and pharmaceutical compositions thereof are provided wherein

30 X_1 is from zero to twelve amino acids, more preferably from

- 5 -

zero to six amino acids, most preferably from zero to three amino acids;

X_2 is from zero to twelve amino acids, more preferably from zero to six amino acids, most preferably from zero to three amino acids; and

5 SEQ ID NO:1 is the sequence Asn-Asn-Ala-Thr-Phe-Tyr-Phe-Lys.

In preferred compounds,

X_1 is

(i) zero amino acids, or

10 (ii) the segment Thr-Leu-Thr-His-Thr-Ile-Thr-Lys-Leu-Asn-Ala-Glu (SEQ ID NO:2), or N-terminal truncation fragment thereof containing at least one amino acid, and

X_2 is

15 (i) zero amino acids, or

(ii) the segment Ile-Asp-Asn-Val-Lys-Lys-Ala-Arg-Val-Gln-Val-Val (SEQ ID NO:3), or C-terminal truncation fragment thereof containing at least one amino acid.

20 According to a further preferred embodiment of the invention, the compound has a substantial amino acid homology to the amino acid sequence Thr-Leu-Thr-His-Thr-Ile-Thr-Lys-Leu-Asn-Ala-Glu-Asn-Asn-Ala-Thr-Phe-Tyr-Phe-Lys-Ile-Asp-Asn-Val-Lys-Lys-Ala-Arg-Val-Gln-Val-Val (SEQ ID NO:4).

25 According to a related invention, compounds of the formula X_3 -SEQ ID NO:5- X_4 and pharmaceutical compositions thereof are provided wherein

X_3 is from zero to twelve amino acids, more preferably from zero to six amino acids, most preferably from zero to three amino acids;

X_4 is from zero to twelve amino acids, more preferably from zero to six amino acids, most preferably from zero to three amino acids;

30 and

SEQ ID NO:5 is the sequence Cys-Val-Gly-Cys, wherein a

- 6 -

disulfide bond between the cysteine residues of SEQ ID NO:5 is optionally present.

In preferred compounds,

X_3 is

5

(i) zero amino acids, or

(ii) the segment Gly-Lys-Asp-Phe-Val-Gln-Pro-Pro-Thr-Lys-Ile (SEQ ID NO:6), or N-terminal truncation fragment thereof containing at least one amino acid, and

10

X_4 is

(i) zero amino acids, or

(ii) the segment Pro-Arg-Asp-Ile-Pro-Thr-Asn-Ser-Pro-Glu-Leu-Glu (SEQ ID NO:7), or C-terminal truncation fragment thereof containing at least one amino acid.

15

According to a further preferred embodiment of the invention, the compound has a substantial amino acid homology to the amino acid sequence Gly-Lys-Asp-Phe-Val-Gln-Pro-Pro-Thr-Lys-Ile-Cys-Val-Gly-Cys-Pro-Arg-Asp-Ile-Pro-Thr-Asn-Ser-Pro-Glu-Leu-Glu (SEQ ID NO:8).

20

According to another related invention, compounds of the formula X_5 -Leu-Asp- X_7 -Asn-Ala-Glu-Val-Tyr- X_6 and pharmaceutical compositions thereof are provided wherein

X_5 is from zero to twelve amino acids, more preferably from zero to six amino acids, most preferably from zero to three amino acids;

25

X_6 is from zero to twelve amino acids, more preferably from zero to six amino acids, most preferably from zero to three amino acids; and

X_7 is Ala or Cys.

Where X_5 and X_6 are zero amino acids, the compounds have the sequences Leu-Asp-Cys-Asn-Ala-Glu-Val-Tyr (SEQ ID NO:21) and Leu-Asp-Ala-Asn-Ala-Glu-Val-Tyr (SEQ ID NO:12).

30

In preferred compounds,

66546106413459

- 7 -

X₅ is

(i) zero amino acids, or

(ii) the segment Thr-Glu-Ser-Cys-Glu-Thr-Lys-Lys-Leu-Gly-Gln-Ser (SEQ ID NO:13), or N-terminal truncation fragment thereof containing at least one amino acid, and

X₆ is

(i) zero amino acids, or

(ii) the segment Val-Val-Pro-Trp-Glu-Lys-Lys-Ile-Tyr-Pro-Thr-Val (SEQ ID NO:14), or C-terminal truncation fragment thereof containing at least one amino acid.

According to a further preferred embodiment of the invention, the compound has a substantial amino acid homology to the amino acid sequence Thr-Glu-Ser-Cys-Glu-Thr-Lys-Lys-Leu-Gly-Gln-Ser-Leu-Asp-Ala-Asn-Ala-Glu-Val-Tyr-Val-Val-Pro-Trp-Glu-Lys-Lys-Ile-Tyr-Pro-Thr-Val (SEQ ID NO:17).

According to a related invention, the compounds Tyr-Phe-Ile-Asp-Phe-Val-Ala-Arg-Glu-Thr-Thr-Cys-Ser-Lys-Glu-Ser (SEQ ID NO:19) and Tyr-Phe-Ile-Asp-Phe-Val-Ala-Arg-Glu-Thr-Thr-Ala-Ser-Lys-Glu-Ser (SEQ ID NO:20) are provided, and pharmaceutical compositions thereof.

The invention is also directed to peptide fragments of the HK domain 3, which fragments inhibit endothelial cell proliferation and thus possess anti-angiogenic activity. In certain embodiments the peptides are from 4 to 40 amino acids in length, preferably 4 to 25 amino acids in length, more preferably from 8 to 15 amino acids in length. The fragments include certain of the compounds described above which represent segments of the HK domain 3. In an embodiment of the invention, one such peptide fragment of HK domain 3 is the compound having the amino acid sequence Tyr-Phe-Ile-Asp-Phe-Val-Ala-Arg-Glu-Thr-Thr-Cys-Ser-Lys-Glu-Ser (SEQ ID NO:19).

The invention is also directed to analogs of such fragments wherein

- 8 -

one or more cysteine residues are replaced with alanine residues to prevent dimerization, e.g., Tyr-Phe-Ile-Asp-Phe-Val-Ala-Arg-Glu-Thr-Thr-Ala-Ser-Lys-Glu-Ser (SEQ ID NO:20).

Preferred compounds include:


- 5 (i) Asn-Asn-Ala-Thr-Phe-Tyr-Phe-Lys (SEQ ID NO:1);
- (ii) Thr-Ile-Thr-Lys-Leu-Asn-Ala-Glu-Asn-Asn-Ala-Thr-Phe-Tyr-Phe-Lys (SEQ ID NO:9);
- (iii) Asn-Asn-Ala-Thr-Phe-Tyr-Phe-Lys-Ile-Asp-Asn-Val-Lys-Lys-Ala-Arg (SEQ ID NO:10);
- 10 (iv) Cys-Val-Gly-Cys (SEQ ID NO:5), wherein a disulfide bond is optionally present between the cysteine residues of SEQ ID NO:5;
- (v) Thr-Lys-Ile-Cys-Val-Gly-Cys-Pro-Arg-Asp-Ile-Pro-Thr-Asn-Ser-Pro (SEQ ID NO:11, wherein a disulfide bond is optionally present between the cysteine residues of said sequence);
- 15 (vi) Leu-Asp-Ala-Asn-Ala-Glu-Val-Tyr (SEQ ID NO:12);
- (vii) Glu-Thr-Lys-Lys-Leu-Gly-Gln-Ser-Leu-Asp-Ala-Asn-Ala-Glu-Val-Tyr (SEQ ID NO:15);
- (viii) Leu-Asp-Ala-Asn-Ala-Glu-Val-Tyr-Val-Val-Pro-Trp-Glu-Lys-Lys-Ile (SEQ ID NO:16);
- 20 (ix) Tyr-Phe-Ile-Asp-Phe-Val-Ala-Arg-Glu-Thr-Thr-Cys-Ser-Lys-Glu-Ser (SEQ ID NO:19); and
- (x) Tyr-Phe-Ile-Asp-Phe-Val-Ala-Arg-Glu-Thr-Thr-Ala-Ser-Lys-Glu-Ser (SEQ ID NO:20).

25 The disulfide bond between the cysteine residues of the compounds containing the Cys-Val-Gly-Cys segment is preferably present. Thus, the peptide of SEQ ID NO:5 preferably has the cyclic structure:



30 and the compounds containing the cyclized SEQ ID NO:5 segment preferably have the structure:

- 9 -



5 The invention also encompasses a method of inhibiting endothelial cell proliferation comprising contacting endothelial cells with the D3-peptides of the present invention.

The invention also encompasses a method of inducing apoptosis of endothelial cells comprising contacting endothelial cells with a D3- peptide.

The invention is also a composition comprising a pharmaceutically effective carrier and a D3-peptide.

10 In the D3-peptides, X_1 , X_2 , X_3 , X_4 , X_5 , and X_6 are chains of amino acids containing from zero to twelve amino acids. The amino acids in each chain may be independently the same or may be different. In other words, each amino acid in the X_n chain may be any amino acid, unless specified otherwise.

15 The invention is also a method of inhibiting angiogenesis in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a composition comprising a pharmaceutically effective carrier and a D3-peptide. The mammal treated is preferably a human being.

20 Other aspects and advantages of the present invention are described in the drawings and in the following detailed description of the preferred embodiments thereof.

Abbreviations and Short Forms

25 The following abbreviations and short forms are used in this specification.

“bFGF” is recombinant human basic fibroblast growth factor.

30 “HK” means the mature form of high molecular weight kininogen, and any allelic variations thereof. By “mature” is meant the post-translationally-modified form of HK which results from cleavage of an eighteen amino acid leader from the initially translated molecule. All

- 10 -

numbering with respect to amino acid positions of HK is from the N-terminus of the mature form as position 1. "HK" is synonymous with "single chain HK", the mature form of high molecular weight kininogen prior to cleavage by kallikrein and the formation of two-chain high molecular weight kininogen.

"HK_a" means two-chain high molecular weight kininogen, the product of kallikrein cleavage of mature high molecular weight kininogen, and any allelic variations thereof.

"HUVEC" means human umbilical vein endothelial cell.

10 Amino Acid Abbreviations

The nomenclature used to describe polypeptide compounds of the present invention follows the conventional practice wherein the amino group is presented to the left and the carboxy group to the right of each amino acid residue. In the formulae representing selected specific embodiments of the present invention, the amino-and carboxy-terminal groups, although not specifically shown, will be understood to be in the form they would assume at physiologic pH values, unless otherwise specified. In the amino acid structure formulae, each residue is generally represented by a one-letter or three-letter designation, corresponding to the trivial name of the amino acid, in accordance with the following schedule:

- 11 -

	A	Alanine	Ala
	C	Cysteine	Cys
	D	Aspartic Acid	Asp
	E	Glutamic Acid	Glu
5	F	Phenylalanine	Phe
	G	Glycine	Gly
	H	Histidine	His
	I	Isoleucine	Ile
	K	Lysine	Lys
10	L	Leucine	Leu
	M	Methionine	Met
	N	Asparagine	Asn
	P	Proline	Pro
	Q	Glutamine	Gln
15	R	Arginine	Arg
	S	Serine	Ser
	T	Threonine	Thr
	V	Valine	Val
	W	Tryptophan	Trp
20	Y	Tyrosine	Tyr

Definitions

The following definitions, of terms used throughout the specification, are intended as an aid to understanding the scope and practice of the present invention.

"Angiogenesis" means the generation of new blood vessels into a tissue or organ.

"Apoptosis" means a process of programmed cell death.

"D3 peptide" means a peptide of the formula (a) X_1 -SEQ ID NO:1- X_2 , (b) X_3 -SEQ ID NO:5- X_4 , (c) X_5 -Leu-Asp- X_7 -Asn-Ala-Glu-Val-Tyr- X_6 were X_1 , X_2 , X_3 , X_4 , X_5 , X_6 and X_7 are defined above, or (d) peptide fragment (or analog thereof) of HK domain 3 which is active in inhibiting endothelial cell proliferation and/or inhibiting angiogenesis.

A **"peptide"** is a compound comprised of amino acid residues covalently linked by peptide bonds.


The expression **"amino acid"** as used herein is meant to include both natural and synthetic amino acids, and both D and L amino acids.

"Natural amino acid" means any of the twenty primary, naturally occurring

- 12 -

amino acids which typically form peptides, polypeptides, and proteins. **"Synthetic amino acid"** means any other amino acid, regardless of whether it is prepared synthetically or derived from a natural source. As used herein, "synthetic amino acid" also encompasses chemically modified amino acids, including but not limited to salts, derivatives (such as amides), and substitutions. Amino acids contained within the peptides of the present invention, and particularly at the carboxy- or amino-terminus, can be modified by methylation, amidation, acetylation or substitution with other chemical groups which can change the peptide's circulating half life without adversely affecting their activity. Additionally, a disulfide linkage may be present or absent in the peptides of the invention, as long as anti-angiogenic activity is maintained.

Amino acids have the following general structure:



Amino acids are classified into seven groups on the basis of the side chain R: (1) aliphatic side chains, (2) side chains containing a hydroxylic (OH) group, (3) side chains containing sulfur atoms, (4) side chains containing an acidic or amide group, (5) side chains containing a basic group, (6) side chains containing an aromatic ring, and (7) proline, an imino acid in which the side chain is fused to the amino group. Peptides comprising a large number of amino acids are sometimes called **"polypeptides"**. The amino acids of the peptides described herein and in the appended claims are understood to be either D or L amino acids with L amino acids being preferred.

"Homology" means similarity of sequence reflecting a common evolutionary origin. Peptides or proteins are said to have homology, or similarity, if a substantial number of their amino acids are either (1)

- 13 -

identical, or (2) have a chemically similar R side chain. Nucleic acids are said to have homology if a substantial number of their nucleotides are identical.

As used herein, **"protected"** with respect to a **terminal amino group** refers to a terminal amino group of a peptide, which terminal amino group is coupled with any of various amino-terminal protecting groups traditionally employed in peptide synthesis. Such protecting groups include, for example, acyl protecting groups such as formyl, acetyl, benzoyl, trifluoroacetyl, succinyl, and methoxysuccinyl; aromatic urethane protecting groups such as benzyloxycarbonyl; and aliphatic urethane protecting groups, for example, tert-butoxycarbonyl or adamantyloxycarbonyl. See Gross and Mienhofer, eds., *The Peptides*, vol. 3, pp. 3-88 (Academic Press, New York, 1981) for suitable protecting groups.

As used herein, **"protected"** with respect to a **terminal carboxyl group** refers to a terminal carboxyl group of a peptide, which terminal carboxyl group is coupled with any of various carboxyl-terminal protecting groups. Such protecting groups include, for example, tert-butyl, benzyl or other acceptable groups linked to the terminal carboxyl group through an ester or ether bond.

"Substantial amino acid sequence homology" means an amino acid sequence homology greater than about 30 %, preferably greater than about 60%, more preferably greater than about 80%, and most preferably greater than about 90 %.

By **"N-terminal truncation fragment"** with respect to an amino acid sequence is meant a fragment obtained from a parent sequence by removing one or more amino acids from the N-terminus thereof.

By **"C-terminal truncation fragment"** with respect to an amino acid sequence is meant a fragment obtained from a parent sequence by removing one or more amino acids from the C-terminus thereof.

- 14 -

Detailed Description of the Invention

According to the present invention, peptide analogs of certain sites in the HK domain 3 inhibit endothelial cell proliferation and may also induce endothelial cell apoptosis. These activities confer upon the D3 peptides the ability to inhibit cytokine-driven angiogenesis *in vivo*.

Antiproliferative effects are observed at concentrations at least as low as 50 μ M.

The mature human HK amino acid sequence is set forth in the recent review by Colman and Schmaier, *Blood*, 90:3819-3843 (1997), for example, the entire disclosure of which is incorporated herein by reference. HK_a generated by plasma kallikrein cleavage of HK differs from HK in that it lacks the nine amino acid segment comprising HK amino acids 363-371. This segment is released from HK as the nonapeptide bradykinin. The two chains of HK resulting from the elimination of bradykinin remain linked by a disulfide bond between cysteine residues at positions 10 and 656 of mature HK. The N-terminal and C-terminal chains of HK_a generated by plasma kallikrein cleavage of HK and release of bradykinin are known as HK "heavy" and "light" chains, respectively.

HK domain 3 spans HK residues 235-357. Located within domain 3 are three segments characterized by the sequences Asn-Asn-Ala-Thr-Phe-Tyr-Phe-Lys (SEQ ID NO:1), Cys-Val-Gly-Cys (SEQ ID NO:5), and Leu-Asp-Cys-Asn-Ala-Glu-Val-Tyr (SEQ ID NO:21) comprising domain 3 amino acids Asn(275)-Lys(282), Cys(246)-Cys(249) and Leu(331)-Tyr(338), respectively. Peptides containing these sequences, or analogs wherein one or more cysteine residues are replaced with alanine residues, inhibit endothelial cell proliferation and are useful as anti-angiogenic agents. The segment Tyr(299)-Ser(314) also inhibits endothelial cell proliferation, as demonstrated by the activity of SEQ ID NO:20, which corresponds to the segment Tyr(299)-Ser(314) but for the substitution of an alanine residue for Cys(310) in the native sequence.

It is believed that the peptides also induce endothelial cell apoptosis.

- 15 -

This contributes to their utility as anti-angiogenic agents.

The D3 peptides may be recombinant peptides, natural peptides, or synthetic peptides. They may also be chemically synthesized, using, for example, solid phase synthesis methods.

5 In conventional solution phase peptide synthesis, the peptide chain can be prepared by a series of coupling reactions in which the constituent amino acids are added to the growing peptide chain in the desired sequence. The use of various N-protecting groups, e.g., the carbobenzyloxy group or the t-butyloxycarbonyl group, various coupling
10 reagents (e.g., dicyclohexylcarbodiimide or carbonyldimidazole, various active esters, e.g., esters of N-hydroxyphthalimide or N-hydroxy-succinimide, and the various cleavage reagents, e.g., trifluoroacetic acid (TFA), HCl in dioxane, boron tris-(trifluoroacetate) and cyanogen bromide, and reaction in solution with isolation and purification of intermediates is
15 well-known classical peptide methodology. The preferred peptide synthesis method follows conventional Merrifield solid-phase procedures. See Merrifield, *J. Amer. Chem. Soc.* 85:2149-54 (1963) and *Science* 50:178-85 (1965). Additional information about the solid phase synthesis procedure can be had by reference to the treatise by Steward and Young (*Solid*
20 *Phase Peptide Synthesis*, W.H. Freeman & Co., San Francisco, 1969, and the review chapter by Merrifield in *Advances in Enzymology* 32:221-296, F.F. Nold, Ed., Interscience Publishers, New York, 1969; and Erickson and Merrifield, *The Proteins* 2:255 et seq. (ed. Neurath and Hill), Academic Press, New York, 1976. The synthesis of peptides by solution methods is
25 described in Neurath et al., eds. (*The Proteins*, Vol. II, 3d Ed., Academic Press, NY (1976)).

Crude peptides may be purified using preparative high performance liquid chromatography. The amino terminus may be blocked according, for example, to the methods described by Yang *et al.* (*FEBS Lett.* 272:61-64
30 (1990)).

Peptide synthesis includes both manual and automated techniques

- 16 -

employing commercially available peptide synthesizers. The D3 peptides of the invention may be prepared by chemical synthesis and biological activity can be tested using the methods disclosed herein.

Alternatively, the D3 peptides may be prepared utilizing recombinant
5 DNA technology, which comprises combining a nucleic acid encoding the peptide thereof in a suitable vector, inserting the resulting vector into a suitable host cell, recovering the peptide produced by the resulting host cell, and purifying the polypeptide recovered. The techniques of recombinant DNA technology are known to those of ordinary skill in the art.
10 General methods for the cloning and expression of recombinant molecules are described in Maniatis (*Molecular Cloning*, Cold Spring Harbor Laboratories, 1982), and in Sambrook (*Molecular Cloning*, Cold Spring Harbor Laboratories, Second Ed., 1989), and in Ausubel (*Current Protocols in Molecular Biology*, Wiley and Sons, 1987), which are incorporated by
15 reference. The complete cDNA of human HK is reported, for example, by Takagi *et al.*, *J. Biol. Chem.* 260:8601-8609 (1985), the entire disclosure of which is incorporated herein by reference. From this nucleic acid sequence, synthetic genes encoding D3-derived peptides may be synthesized directly on a DNA synthesizer, or may be synthesized as
20 complementary oligonucleotides which are ligated together to form the synthetic gene.

The nucleic acids encoding D3-derived peptides may be operatively linked to one or more regulatory regions. Regulatory regions include
25 promoters, polyadenylation signals, translation initiation signals (Kozak regions), termination codons, peptide cleavage sites, and enhancers. The regulatory sequences used must be functional within the cells of the vertebrate to be immunized. Selection of the appropriate regulatory region or regions is a routine matter, within the level of ordinary skill in the art.

Promoters that may be used in the present invention include both
30 constitutive promoters and regulated (inducible) promoters. The promoters may be prokaryotic or eukaryotic depending on the host. Among the

- 17 -

prokaryotic (including bacteriophage) promoters useful for practice of this invention are *lacI*, *lacZ*, T3, T7, *lambda Pr'* *PI'* and *trp* promoters. Among the eukaryotic (including viral) promoters useful for practice of this invention are ubiquitous promoters (e.g. HPRT, vimentin, actin, tubulin), intermediate
5 filament promoters (e.g. desmin, neurofilaments, keratin, GFAP), therapeutic gene promoters (e.g. MDR type, CFTR, factor VIII), tissue-specific promoters (e.g. actin promoter in smooth muscle cells), promoters which respond to a stimulus (e.g. steroid hormone receptor, retinoic acid receptor), tetracycline-regulated transcriptional modulators,
10 cytomegalovirus immediate-early, retroviral LTR, metallothionein, SV-40, E1a, and MLP promoters. Tetracycline-regulated transcriptional modulators and CMV promoters are described in WO 96/01313, US 5,168,062 and 5,385,839, the entire disclosures of which are incorporated herein by reference.

15 Examples of polyadenylation signals that can be used in the present invention include but are not limited to SV40 polyadenylation signals and LTR polyadenylation signals.

The D3 peptides prepared by either chemical synthesis or recombinant DNA technology may then be assayed for biological activity
20 according to the assay methods described herein.

In some embodiments, the peptides of the present invention may be used in the form of a pharmaceutically acceptable salt.

Suitable acids which are capable of forming salts with the peptides include inorganic acids such as hydrochloric acid, hydrobromic acid,
25 perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid and the like; and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, anthranilic acid, cinnamic acid, naphthalene sulfonic acid, sulfanilic acid and the like.

30 Suitable bases capable of forming salts with the peptides include inorganic bases such as sodium hydroxide, ammonium hydroxide,

- 18 -

potassium hydroxide and the like; and organic bases such as mono-, di- and tri-alkyl and aryl amines (e.g., triethylamine, diisopropyl amine, methyl amine, dimethyl amine and the like) and optionally substituted ethanolamines (e.g., ethanolamine, diethanolamine and the like).

5 The present invention provides methods for inhibiting angiogenesis. A preferred embodiment is a method of inhibiting the proliferation of endothelial cells, or obtaining apoptosis of such cells. Accordingly, D3 peptides is administered to a patient in need of such treatment. A therapeutically effective amount of the drug may be administered as a
10 composition in combination with a pharmaceutically carrier.

 Pharmaceutically acceptable carriers include physiologically tolerable or acceptable diluents, excipients, solvents, adjuvants, or vehicles, for parenteral injection, for intranasal or sublingual delivery, for oral administration, for rectal or topical administration or the like. The
15 compositions are preferably sterile and nonpyrogenic. Examples of suitable carriers include but are not limited to water, saline, dextrose, mannitol, lactose, or other sugars, lecithin, albumin, sodium glutamate cysteine hydrochloride, ethanol, polyols (propyleneglycol, ethylene, polyethyleneglycol, glycerol, and the like), vegetable oils (such as olive oil),
20 injectable organic esters such as ethyl oleate, ethoxylated isosteraryl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.

 The pharmaceutical compositions may also contain minor amounts
25 of nontoxic auxiliary substances such as wetting agents, emulsifying agents, pH buffering agents, antibacterial and antifungal agents (such as parabens, chlorobutanol, phenol, sorbic acid, and the like). If desired, absorption enhancing or delaying agents (such as liposomes, aluminum monostearate, or gelatin) may be used. The compositions can be prepared
30 in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as

- 19 -

emulsions.

Compositions containing the anti-angiogenic D3 peptides may be administered by any convenient route which will result in delivery to the site of undesired angiogenesis in an amount effective for inhibiting that angiogenesis from proceeding. Modes of administration include, for example, orally, rectally, parenterally (intravenously, intramuscularly, intraarterially, or subcutaneously), intracisternally, intravaginally, intraperitoneally, locally (powders, ointments or drops), or as a buccal or nasal spray or aerosol. The compositions can also be delivered through a catheter for local delivery at a target site, or via a biodegradable polymer. The compositions may also be complexed to ligands, or antibodies, for targeted delivery of the compositions.

The compositions are most effectively administered parenterally, preferably intravenously or subcutaneously. For intravenous administration, they may be dissolved in any appropriate intravenous delivery vehicle containing physiologically compatible substances, such as sodium chloride, glycine, and the like, having a buffered pH compatible with physiologic conditions. Such intravenous delivery vehicles are known to those skilled in the art. In a preferred embodiment, the vehicle is a sterile saline solution. If the peptides are sufficiently small (e.g., less than about 8-10 amino acids) other preferred routes of administration are intranasal, sublingual, and the like. Intravenous or subcutaneous administration may comprise, for example, injection or infusion.

The compositions according to the invention can be administered in any circumstance in which inhibition of angiogenesis is desired. Disease states which may be treated include but are not limited to cancer, rheumatoid arthritis, and certain ocular disorders characterized by undesired vascularization of the retina. Because the peptides of the invention are anti-angiogenic, cancers characterized by the growth of solid tumors through angiogenesis of the tissue surrounding the tumor site may be treated according to the invention. The compositions according to the

- 20 -

invention may be administered to a tumor, for example, by direct injection into the tumor, or the tissues surrounding the tumor.

The amount of active agent administered depends upon the degree of the anti-angiogenic effect desired. Those skilled in the art will derive appropriate dosages and schedules of administration to suit the specific circumstances and needs of the patient. Typically, dosages are from about 0.1 to about 100, preferably from about 0.5 to about 50, most preferably from about 1 to about 20, mg/kg of body weight. The active agent may be administered by injection daily, over a course of therapy lasting two to three weeks, for example. Alternatively, the agent may be administered by continuous infusion, such as via an implanted subcutaneous pump.

Peptides which inhibit endothelial cell proliferation with an IC₅₀ of no more than about 100 μ M, more preferably no more than about 50 μ M, most preferably no more than about 10 μ M, are preferred. For purposes of this preference, IC₅₀ is determined according to the procedure and formula set forth in Examples 1-6, below.

The practice of the present invention is illustrated by the following non-limiting examples.

Examples

Materials

The materials utilized in the Examples were sourced as follows. Tissue culture medium and reagents were obtained from Mediatech (Herndon, VA). Fetal bovine serum was from Hyclone (Logan, Utah). Recombinant human basic fibroblast growth factor (bFGF), was obtained from Collaborative Biomedical Products/Becton Dickinson (Bedford, MA). Gelatin was purchased from Sigma (St. Louis, MO).

Synthetic Peptides

Synthetic peptides were synthesized on a Rainin Symphony multiple peptide synthesizer, using Fmoc chemistry. All resins (AnaSpec) used for solid phase synthesis were Wang resins preloaded with the first amino

- 21 -

acid. Fmoc amino acids were purchased from Perseptive Biosystems, with side chain protective groups as follows: trityl (Asn, Cys, Gln, and His), Boc (Lys and Trp), Ombu (Asp and Glu), T.U. (Ser, Thr and Tyr) and P.G. (Arg). Deprotection of the Fmoc group was performed in piperidine in dimethylformamide (DMF). Coupling was carried out done in HBTU in N-methylmorpholine/DMF as the activator. Standard synthesis cycles were 3 x 30" washes with DMF, 3 x 15" deprotection with piperidine, 6 x 20" DMF washes, 45 minute coupling with amino acid and activator followed by 3 x 30" DMF washes.

Peptides were cleaved off the solid phase support with cleavage cocktail consisting of 88:5:5:2 (TFA:water:phenol: triisopropylsilane). Cleavage was done on the synthesizer. Peptides were precipitated with ether, pelleted by centrifugation, washed three times with ether and then allowed to dry. HPLC was carried out on a Beckman HPLC system using Rainin Dynamax Reversed Phase columns and an acetonitrile gradient in water. The desired peptide was detected during elution by off line MALDI-TOF mass spectrophotometry using a Perseptive Biosystems Voyager instrument. Purified peptides were lyophilized and then reanalyzed by MALDI-TOF mass spectrophotometry.

Cell Culture Methods

Human umbilical vein endothelial cells (HUVEC) were isolated and cultured as previously described (Graham *et al.*, *Blood* 91:3300-7 1998). Cells were of passage 3 or lower.

Examples 1-6

Effect of HK Domain 3 Peptide on Endothelial Cell Proliferation

A. Experimental

To assess the effect of peptides on endothelial cell proliferation, HUVEC were suspended at a concentration of 30,000 cells/ml in M199

- 22 -

containing 2% FCS. One hundred microliters of this suspension was then plated in individual wells of a 96 well microplate precoated with 1% gelatin. After incubation for 2 hours, at 37°C, to allow cells to adhere and spread, medium was removed and replaced with fresh M199 containing (i) 2% FCS, 5 (ii) 10 µM ZnCl₂, (iii) 10 ng/ml bFGF as a growth factor, and (iv) 5, 10, 25 or 50 µM of one of the following D3 peptides:

Thr-Ile-Thr-Lys-Leu-Asn-Ala-Glu-Asn-Asn-Ala-Thr-Phe-Tyr-Phe-Lys
(SEQ ID NO:9);
Asn-Asn-Ala-Thr-Phe-Tyr-Phe-Lys-Ile-Asp-Asn-Val-Lys-Lys-Ala-Arg
10 (SEQ ID NO:10);
Thr-Lys-Ile-Cys-Val-Gly-Cys-Pro-Arg-Asp-Ile-Pro-Thr-Asn-Ser-Pro
(SEQ ID NO:11);
Glu-Thr-Lys-Lys-Leu-Gly-Gln-Ser-Leu-Asp-Ala-Asn-Ala-Glu-Val-Tyr
(SEQ ID NO:15);
15 Leu-Asp-Ala-Asn-Ala-Glu-Val-Tyr-Val-Val-Pro-Trp-Glu-Lys-Lys-Ile
(SEQ ID NO:16); and
Tyr-Phe-Ile-Asp-Phe-Val-Ala-Arg-Glu-Thr-Thr-Ala-Ser-Lys-Glu-Ser
(SEQ ID NO:20).

Cells were then incubated for 48 hours at 37°C, at which time the relative
20 numbers of cells in each well were determined using the Cell Titer® Aq_{ueous}
cell proliferation assay (Promega, Madison, WI). Briefly, 20 µl of a 19:1
(V/V) mixture of (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethylphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium (MTS) and phenazine methosulfate (PMS)
was added to each well, and after an additional hour of incubation, A₄₉₀
25 was measured using a BioRad model EL311 microplate reader. The
percent inhibition of cell proliferation by each peptide was determined using
the formula:

$$\% \text{ inhibition} = (1 - [(A_{490 (+GF, D3)} - A_{490 (-GF)}) / (A_{490 (+GF)} - A_{490 (-GF)})]) \times 100,$$

- 23 -

where (+GF) and (-GF) represent proliferation in the presence or absence of added growth factor bFGF, and (+GF, D3) represents proliferation in the presence of both growth factor and D3 peptide. The significance of differences in relative endothelial cell proliferation cell numbers at the end of the proliferation assays was determined using the Student's two-tailed T-test for paired samples. The IC50 was then calculated for each compound. Due to peptide losses during filtration, the IC50 for SEQ ID NO:9 and SEQ ID NO:10 are estimates, based upon the assumption that since these peptides contain one tyrosine residue, a 1 mM peptide concentration should have an absorbance at A_{280} of 1.28.

B. Results

The IC50 for inhibition of endothelial cell proliferation attributable to each peptide is given in Table 1. Each compound is effective at inhibiting endothelial cell proliferation.

15 Endothelial cell proliferation is a hallmark of angiogenesis. The inhibition of bFGF-induced endothelial cell proliferation is an accepted model of angiogenesis. Thus, the results demonstrated herein establish the anti-angiogenic activity of the D3 peptides, and their utility in medicine for inhibiting undesired angiogenesis.

- 24 -

Table 1**Inhibition of Endothelial Cell Proliferation by D3 Peptides**

	Example	Inhibitor	IC50 (μM)
	1	SEQ ID NO:9	<0.8
5	2	SEQ ID NO:10	<0.8
	3	SEQ ID NO:11	30
	4	SEQ ID NO:15	42
	5	SEQ ID NO:16	44
	6	SEQ ID NO:20	28

10 All references discussed herein are incorporated by reference. One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The present invention may be embodied in other specific forms without departing from the spirit or

15 essential attributes thereof and, accordingly, reference should be made to the appended claims, rather than to the foregoing specification, as indicating the scope of the invention.

- 25 -

CLAIMS

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula X_1 -Asn-Asn-Ala-Thr-Phe-Tyr-Phe-Lys- X_2 wherein

- 5 X_1 is from zero to twelve amino acids, and
 X_2 is from zero to twelve amino acids,

and wherein said compound optionally comprises an amino-terminal and/or carboxy-terminal protecting group.

2. The composition of claim 1 wherein

- 10 X_1 is from zero to six amino acids, and
 X_2 is from zero to six amino acids.

3. The composition of claim 1 wherein

X_1 is

- 15 (i) zero amino acids, or
 (ii) the segment Thr-Leu-Thr-His-Thr-Ile-Thr-Lys-Leu-Asn-Ala-Glu, or N-terminal truncation fragment thereof containing at least one amino acid, and

X_2 is

- 20 (i) zero amino acids, or
 (ii) the segment Ile-Asp-Asn-Val-Lys-Lys-Ala-Arg-Val-Gln-Val-Val, or C-terminal truncation fragment thereof containing at least one amino acid.

4. The composition of claim 1 wherein the compound has

06056-0260 US

- 26 -

substantial amino acid sequence homology to the amino acid sequence Thr-Leu-Thr-His-Thr-Ile-Thr-Lys-Leu-Asn-Ala-Glu-Asn-Asn-Ala-Thr-Phe-Tyr-Phe-Lys-Ile-Asp-Asn-Val-Lys-Lys-Ala-Arg-Val-Gln-Val-Val.

5. The composition of claim 1 wherein the compound has the amino acid sequence Asn-Asn-Ala-Thr-Phe-Tyr-Phe-Lys.

6. The composition of claim 1 wherein the compound has the amino acid sequence Thr-Ile-Thr-Lys-Leu-Asn-Ala-Glu-Asn-Asn-Ala-Thr-Phe-Tyr-Phe-Lys.

7. The composition of claim 1 wherein the compound has the amino acid sequence Asn-Asn-Ala-Thr-Phe-Tyr-Phe-Lys-Ile-Asp-Asn-Val-Lys-Lys-Ala-Arg.

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula X_3 -Cys-Val-Gly-Cys- X_4 wherein

X_3 is from zero to twelve amino acids, and
 X_4 is from zero to twelve amino acids,

wherein a disulfide bond between the cysteine residues of the segment Cys-Val-Gly-Cys is optionally present, and wherein said compound optionally comprises an amino-terminal and/or carboxy-terminal protecting group.

9. The composition of claim 8 wherein
 X_3 is from zero to six amino acids, and
 X_4 is from zero to six amino acids.

10. The composition of claim 8 wherein

- 27 -

X_3 is

- (i) zero amino acids, or
- (ii) the segment Gly-Lys-Asp-Phe-Val-Gln-Pro-Pro-Thr-Lys-Ile, or N-terminal truncation fragment thereof containing at least one amino acid, and

X_4 is

- (i) zero amino acids, or
- (ii) the segment Pro-Arg-Asp-Ile-Pro-Thr-Asn-Ser-Pro-Glu-Leu-Glu, or C-terminal truncation fragment thereof containing at least one amino acid.

11. The composition of claim 8 wherein the compound has substantial amino acid sequence homology to the amino acid sequence Pro-Gln-Lys-Asp-Phe-Val-Gln-Pro-Pro-Thr-Lys-Ile-Cys-Val-Gly-Cys-Pro-Arg-Asp-Ile-Pro-Thr-Asn-Ser-Pro-Glu-Leu-Glu

12. The composition of claim 8 wherein the compound has the amino acid sequence Cys-Val-Gly-Cys.

13. The composition of claim 8 wherein the compound has the amino acid sequence Thr-Lys-Ile-Cys-Val-Gly-Cys-Pro-Arg-Asp-Ile-Pro-Thr-Asn-Ser-Pro.

14. The composition of any of claims 8-13 wherein a disulfide bond between the cysteine residues of the segment Cys-Val-Gly-Cys of said compound is present.

15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula X_5 -Leu-Asp- X_7 -Asn-Ala-Glu-Val-Tyr- X_6 wherein

- 28 -

X₅ is from zero to twelve amino acids,
X₆ is from zero to twelve amino acids, and
X₇ is Ala or Cys,

and wherein said compound optionally comprises an amino-terminal and/or
5 carboxy-terminal protecting group.

16. The composition of claim 15 wherein

X₅ is from zero to six amino acids, and
X₆ is from zero to six amino acids.

17. The composition of claim 15 wherein

10

X₅ is

(i) zero amino acids, or

(ii) the segment Thr-Glu-Ser-Cys-Glu-Thr-Lys-Lys-Leu-
Gly-Gln-Ser, or N-terminal truncation fragment thereof
containing at least one amino acid, and

15

X₆ is

(i) zero amino acids, or

(ii) the segment Val-Val-Pro-Trp-Glu-Lys-Lys-Ile-Tyr-
Pro-Thr-Val, or C-terminal truncation fragment thereof
20 containing at least one amino acid.

- 29 -

18. The composition of claim 15 wherein the compound has substantial amino acid sequence homology to the amino acid sequence Thr-Glu-Ser-Cys-Glu-Thr-Lys-Lys-Leu-Gly-Gln-Ser-Leu-Asp-Ala-Asn-Ala-Glu-Val-Tyr-Val-Val-Pro-Trp-Glu-Lys-Lys-Ile-Tyr-Pro-Thr-Val.

5 19. The composition of claim 15 wherein the compound has the amino acid sequence Leu-Asp-Ala-Asn-Ala-Glu-Val-Tyr.

20. The composition of claim 15 wherein the compound has the amino acid sequence Glu-Thr-Lys-Lys-Leu-Gly-Gln-Ser-Leu-Asp-Ala-Asn-Ala-Glu-Val-Tyr.

10 21. The composition of claim 15 wherein the compound has the amino acid sequence Leu-Asp-Ala-Asn-Ala-Glu-Val-Tyr-Val-Val-Pro-Trp-Glu-Lys-Lys-Ile.

22. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a peptide fragment of high molecular weight
15 kininogen domain 3, or analog of such a peptide fragment wherein one or more cysteine residues in the fragment are replaced by alanine residues, which peptide fragment or analog inhibits endothelial cell proliferation and optionally comprises an amino-terminal and/or carboxy-terminal protecting group.

20

23. The composition according to claim 22 wherein the peptide fragment or analog has the amino acid sequence Tyr-Phe-Ile-Asp-Phe-Val-Ala-Arg-Glu-Thr-Thr-Cys-Ser-Lys-Glu-Ser or Tyr-Phe-Ile-Asp-Phe-Val-Ala-Arg-Glu-Thr-Thr-Ala-Ser-Lys-Glu-Ser.

25 24. A method of inhibiting angiogenesis comprising administering to a mammal an effective amount of a composition according to claim 1.

- 30 -

25. A method of inhibiting endothelial cell proliferation comprising administering to a mammal an effective amount of a composition according to claim 1.

26. A method of inducing endothelial cell apoptosis comprising
5 administering to a mammal an effective amount of a compound according to claim 1.

27. A method of inhibiting endothelial cell proliferation comprising contacting endothelial cells with a compound of the formula X_1 -Asn-Asn-Ala-Thr-Phe-Tyr-Phe-Lys- X_2 wherein
10 X_1 is from zero to twelve amino acids, and
 X_2 is from zero to twelve amino acids,

and wherein said compound optionally comprises an amino-terminal and/or carboxy-terminal protecting group.

28. The method of claim 27 wherein
15 X_1 is from zero to six amino acids, and
 X_2 is from zero to six amino acids.

29. The method of claim 27 wherein
 X_1 is
(i) zero amino acids, or
20 (ii) the segment Thr-Leu-Thr-His-Thr-Ile-Thr-Lys-Leu-Asn-Ala-Glu, or N-terminal truncation fragment thereof containing at least one amino acid, and

- 31 -

X_2 is

(i) zero amino acids, or

(ii) the segment Ile-Asp-Asn-Val-Lys-Lys-Ala-Arg-Val-Gln-Val-Val, or C-terminal truncation fragment thereof containing at least one amino acid.

5

30. The method of claim 27 wherein the compound has the amino acid sequence Thr-Ile-Thr-Lys-Leu-Asn-Ala-Glu-Asn-Asn-Ala-Thr-Phe-Tyr-Phe-Lys.

31. The method of claim 27 wherein the compound has the amino acid sequence Asn-Asn-Ala-Thr-Phe-Tyr-Phe-Lys-Ile-Asp-Asn-Val-Lys-Lys-Ala-Arg.

10

32. A method of inhibiting endothelial cell proliferation comprising contacting endothelial cells with a compound of the formula X_3 -Cys-Val-Gly-Cys- X_4 wherein

15

X_3 is from zero to twelve amino acids, and
 X_4 is from zero to twelve amino acids,

wherein a disulfide bond between the cysteine residues of the segment Cys-Val-Gly-Cys is optionally present, and wherein said compound optionally comprises an amino-terminal and/or carboxy-terminal protecting group.

20

- 32 -

33. The method of claim 32 wherein

X_1 is from zero to six amino acids, and

X_2 is from zero to six amino acids.

34. The method of claim 32 wherein

5 X_3 is

(i) zero amino acids, or

(ii) the segment Gly-Lys-Asp-Phe-Val-Gln-Pro-Pro-Thr-Lys-Ile, or N-terminal truncation fragment thereof containing at least one amino acid, and

10

X_4 is

(i) zero amino acids, or

(ii) the segment Pro-Arg-Asp-Ile-Pro-Thr-Asn-Ser-Pro-Glu-Leu-Glu, or C-terminal truncation fragment thereof containing at least one amino acid.

15

35. The method of claim 32 wherein the compound has the amino acid sequence Cys-Val-Gly-Cys.

36. The method of claim 32 wherein the compound has the amino acid sequence Thr-Lys-Ile-Cys-Val-Gly-Cys-Pro-Arg-Asp-Ile-Pro-Thr-Asn-Ser-Pro.

20

37. The method of any of claims 32-36 wherein a disulfide bond between the cysteine residues of the segment Cys-Val-Gly-Cys of said compound is present.

38. A method of inhibiting endothelial cell proliferation comprising

- 33 -

contacting endothelial cells with a compound of the formula X_5 -Leu-Asp- X_7 -Asn-Ala-Glu-Val-Tyr- X_6 wherein

- 5 X_5 is from zero to twelve amino acids,
 X_6 is from zero to twelve amino acids, and
 X_7 is Ala or Cys.

and wherein said compound optionally comprises an amino-terminal and/or carboxy-terminal protecting group.

39. The method of claim 38 wherein
- 10 X_5 is from zero to six amino acids, and
 X_6 is from zero to six amino acids.
40. The method of claim 38 wherein
- X_5 is
- (i) zero amino acids, or
- (ii) the segment Thr-Glu-Ser-Cys-Glu-Thr-Lys-Lys-
15 Leu-Gly-Gln-Ser, or N-terminal truncation fragment thereof
 containing at least one amino acid, and
- X_6 is
- (i) zero amino acids, or
- 20 (ii) the segment Val-Val-Pro-Trp-Glu-Lys-Lys-Ile-Tyr-
 Pro-Thr-Val, or C-terminal truncation fragment thereof
 containing at least one amino acid.
41. The method of claim 38 wherein the compound has the amino acid sequence Leu-Asp-Ala-Asn-Ala-Glu-Val-Tyr.

- 34 -

42. The method of claim 38 wherein the compound has the amino acid sequence Glu-Thr-Lys-Lys-Leu-Gly-Gln-Ser-Leu-Asp-Ala-Asn-Ala-Glu-Val-Tyr.

43. The method of claim 38 wherein the compound has the amino acid sequence Leu-Asp-Ala-Asn-Ala-Glu-Val-Tyr-Val-Val-Pro-Trp-Glu-Lys-Lys-Ile.

44. A method of inhibiting endothelial cell proliferation comprising contacting endothelial cells with a peptide fragment of high molecular weight kininogen domain 3, or analog of such a peptide fragment wherein one or more cysteine residues in the fragment are replaced by alanine residues, wherein said compound optionally comprises an amino-terminal and/or carboxy-terminal protecting group.

45. The method according to claim 44 wherein the peptide has the amino acid sequence Tyr-Phe-Ile-Asp-Phe-Val-Ala-Arg-Glu-Thr-Thr-Cys-Ser-Lys-Glu-Ser or Tyr-Phe-Ile-Asp-Phe-Val-Ala-Arg-Glu-Thr-Thr-Ala-Ser-Lys-Glu-Ser.

**INHIBITION OF ANGIOGENESIS BY HIGH MOLECULAR
WEIGHT KININOGEN DOMAIN 3 PEPTIDE ANALOGS**

Abstract of the Disclosure

Peptide analogs the high molecular weight kininogen domain 3 are
5 potent inhibitors of angiogenesis. The peptides have the formula (a) X_1 -
Asn-Asn-Ala-Thr-Phe-Tyr-Phe-Lys- X_2 , (b) X_3 -Cys-Val-Gly-Cys- X_4 , (c) X_5 -
Leu-Asp- X_7 -Asn-Ala-Glu-Val-Tyr- X_6 , or (d) Tyr-Phe-Ile-Asp-Phe-Val-Ala-
Arg-Glu-Thr-Thr- X_7 -Ser-Lys-Glu-Ser

wherein:

10 X_1 , X_2 , X_3 , X_4 , X_5 , and X_6 are from zero to twelve amino acids,
independently the same or different, more preferably from zero to
six amino acids, and;
 X_7 is Ala or Cys.

The peptides may also comprise biologically active fragments of high
15 molecular weight kininogen domain 3. Methods of inhibiting endothelial cell
proliferation and angiogenesis are provided.

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are stated below next to my name.

I believe I am the original, first, and sole inventor (if only one name is listed below) or an original, first, and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

**INHIBITION OF ANGIOGENESIS BY HIGH MOLECULAR WEIGHT KININOGEN DOMAIN
3 PEPTIDE ANALOGS**

the specification of which is attached hereto.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with 37 CFR §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S)

COUNTRY/OFFICE	APPLICATION NO.	DATE OF FILING	PRIORITY CLAIMED
None			<input type="checkbox"/> YES NO <input type="checkbox"/>
			<input type="checkbox"/> YES NO <input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

PROVISIONAL APPLICATION NUMBER**DATE OF FILING**

60/112,427

16 December 1998

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or §365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose material information as defined in 37 CFR §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

**PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS
DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. §120**

Application Serial No.	Date of Filing	Status (check one)		
		Patented	Pending	Abandoned
none		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

And I hereby appoint Arthur H. Seidel, Registration No. 15,979; Gregory J. Lavorgna, Registration No. 30,469; Daniel A. Monaco, Registration No. 30,480; Thomas J. Durling, Registration No. 31,349; and John J. Marshall, Registration No. 29,671, my attorneys or agents with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Address all correspondence to Seidel, Gonda, Lavorgna & Monaco, P.C., Suite 1800, Two Penn Center Plaza, Philadelphia, Pennsylvania 19102. Address all telephone calls to Daniel A. Monaco (215)568-8383 (telefax: 215-568-5549).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF SOLE OR FIRST INVENTOR

Keith _____ R. _____ McCrae _____
(GIVEN NAME) (MIDDLE INITIAL OR NAME) (FAMILY OR LAST NAME)

Inventor's signature: Keith R McCrae

Date: 11/30/99

Country of Citizenship: United States

Residence: Chagrin Falls Ohio
(City) (State or Foreign Country)

Post Office Address: 38275 Fairmount Boulevard, Chagrin Falls, Ohio 44022

SEQUENCE LISTING

<110> McCrae, Keith R.

<120> Inhibition of Angiogenesis By High Molecular Weight
Kininogen Domain 3 Peptide Analogs

<130> 6056-260 US

<140>

<141>

<150> 60/112,427

<151> 1998-12-16

<160> 21

<170> PatentIn Ver. 2.0

<210> 1

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Human high
molecular weight kininogen (HK) fragment from
domain 3 thereof

<400> 1

Asn Asn Ala Thr Phe Tyr Phe Lys

1

5

<210> 2

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fragment of
human HK domain 3

<400> 2

Thr Leu Thr His Thr Ile Thr Lys Leu Asn Ala Glu

1

5

10

<210> 3
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Fragment of
human HK domain 3

<400> 3
Ile Asp Asn Val Lys Lys Ala Arg Val Gln Val Val
1 5 10

<210> 4
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Fragment of
human HK domain 3

<400> 4
Thr Leu Thr His Thr Ile Thr Lys Leu Asn Ala Glu Asn Asn Ala Thr
1 5 10 15

Phe Tyr Phe Lys Ile Asp Asn Val Lys Lys Ala Arg Val Gln Val Val
20 25 30

<210> 5
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Fragment of
human HK domain 3

<400> 5
Cys Val Gly Cys
1

<210> 6
<211> 11
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fragment of
human HK domain 3

<400> 6
Gly Lys Asp Phe Val Gln Pro Pro Thr Lys Ile
1 5 10

<210> 7
<211> 12
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fragment of
human HK domain 3

<400> 7
Pro Arg Asp Ile Pro Thr Asn Ser Pro Glu Leu Glu
1 5 10

<210> 8
<211> 27
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fragment of
human HK domain 3

<400> 8
Gly Lys Asp Phe Val Gln Pro Pro Thr Lys Ile Cys Val Gly Cys Pro
1 5 10 15

Arg Asp Ile Pro Thr Asn Ser Pro Glu Leu Glu
20 25

<210> 9
<211> 16
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fragment of
human HK domain 3

<400> 9

Thr	Ile	Thr	Lys	Leu	Asn	Ala	Glu	Asn	Asn	Ala	Thr	Phe	Tyr	Phe	Lys
1				5					10					15	

<210> 10

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fragment of
human HK domain 3

<400> 10

Asn	Asn	Ala	Thr	Phe	Tyr	Phe	Lys	Ile	Asp	Asn	Val	Lys	Lys	Ala	Arg
1				5					10					15	

<210> 11

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fragment of
human HK domain 3

<400> 11

Thr	Lys	Ile	Cys	Val	Gly	Cys	Pro	Arg	Asp	Ile	Pro	Thr	Asn	Ser	Pro
1				5					10					15	

<210> 12

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Analog of
human HK domain 3 fragment

<400> 12

Leu Asp Ala Asn Ala Glu Val Tyr

1

5

<210> 13

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fragment of
human HK domain 3

<400> 13

Thr Glu Ser Cys Glu Thr Lys Lys Leu Gly Gln Ser

1

5

10

<210> 14

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fragment of
human HK domain 3

<400> 14

Val Val Pro Trp Glu Lys Lys Ile Tyr Pro Thr Val

1

5

10

<210> 15

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fragment of
human HK domain 3

<400> 15

Glu Thr Lys Lys Leu Gly Gln Ser Leu Asp Ala Asn Ala Glu Val Tyr

1

5

10

15

<210> 16

<211> 16
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Analog of
human HK domain 3 fragment

<400> 16

Leu Asp Ala Asn Ala Glu Val Tyr Val Val Pro Trp Glu Lys Lys Ile
1 5 10 15

<210> 17

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Analog of
human HK domain 3 fragment

<400> 17

Thr Glu Ser Cys Glu Thr Lys Lys Leu Gly Gln Ser Leu Asp Ala Asn
1 5 10 15

Ala Glu Val Tyr Val Val Pro Trp Glu Lys Lys Ile Tyr Pro Thr Val
20 25 30

<210> 18

<211> 123

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Human HK
domain 3

<400> 18

Gly Lys Asp Phe Val Gln Pro Pro Thr Lys Ile Cys Val Gly Cys Pro
1 5 10 15

Arg Asp Ile Pro Thr Asn Ser Pro Glu Leu Glu Glu Thr Leu Thr His
20 25 30

Thr Ile Thr Lys Leu Asn Ala Glu Asn Asn Ala Thr Phe Tyr Phe Lys
 35 40 45

Ile Asp Asn Val Lys Lys Ala Arg Val Gln Val Val Ala Gly Lys Lys
 50 55 60

Tyr Phe Ile Asp Phe Val Ala Arg Glu Thr Thr Cys Ser Lys Glu Ser
 65 70 75 80

Asn Glu Glu Leu Thr Glu Ser Cys Glu Thr Lys Lys Leu Gly Gln Ser
 85 90 95

Leu Asp Cys Asn Ala Glu Val Tyr Val Val Pro Trp Glu Lys Lys Ile
 100 105 110

Tyr Pro Thr Val Asn Cys Gln Pro Leu Gly Met
 115 120

<210> 19

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Human HK
 domain 3

<400> 19

Tyr Phe Ile Asp Phe Val Ala Arg Glu Thr Thr Cys Ser Lys Glu Ser
 1 5 10 15

<210> 20

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Analog of
 human HK domain 3 fragment

<400> 20

Tyr Phe Ile Asp Phe Val Ala Arg Glu Thr Thr Ala Ser Lys Glu Ser
 1 5 10 15

<210> 21

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fragment of
human HK domain 3

<400> 21

Leu Asp Cys Asn Ala Glu Val Tyr

1

5